FranceU članku se raspravlja o izazovima s kojima se suočavaju farmaceutski kandidati u kliničkim ispitivanjima, napominjući da samo jedan od deset lijekova uspješno napreduje do odobrenja na tržište.
Procjena pristranosti (Sredina): U članku su predstavljene informacije o primjeni umjetne inteligencije u kliničkim istraživanjima, bez da se otvoreno favorizira neka određena politička ideologija ili grupa dionika.
Zašto činjenice (85): The article discusses the use of AI-generated virtual patients and digital twins in clinical trials, citing a statistic that only one out of ten drug candidates successfully progresses to market. While no primary source is available, this claim aligns with general industry knowledge and cross-source
Zašto objektivnost (75): The tone is informative and forward-looking, focusing on the potential benefits of AI in clinical research. It presents the topic objectively but includes some speculative language such as 's'invitent dans les essais cliniques,' which suggests an optimistic view of the technology's role. There is no
